IL2 and metastatic melanoma: In the present prospective randomized trial we reported the results of 124 patients with progressive metastatic melanoma who received a combined chemoimmunotherapy (IFN-, IL-2 combined with DTIC, cisplatin, BCNU, and tamoxifen) or a chemotherapy (DTIC, cisplatin, BCNU, and tamoxifen) alone.